Date | Price Target | Rating | Analyst |
---|---|---|---|
8/16/2023 | Market Perform | SVB Securities | |
8/15/2023 | $20.00 | Overweight | Piper Sandler |
8/15/2023 | $18.00 | Buy | BofA Securities |
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)
10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. "We have continued to bolster our position
Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing successProduct characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
SVB Securities initiated coverage of Turnstone Biologics with a rating of Market Perform
Piper Sandler initiated coverage of Turnstone Biologics with a rating of Overweight and set a new price target of $20.00
BofA Securities initiated coverage of Turnstone Biologics with a rating of Buy and set a new price target of $18.00
Gainers Larimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock rose 6.53% to $8.31. The company's market cap stands at $11.4 million. As per the press release, Q1 earnings came out 3 days ago. DermTech (NASDAQ:DMTK) shares moved upwards by 5.52% to $0.38. The market value of their outstanding shares is at $13.2 million. As per the news, the Q1 earnings report came out 4 days ago. BiomX (AMEX:PHGE) shares rose 5.38% to $0.36. The company's market cap stands at $19.8 million. Sharecare (NASDAQ:SHCR) shares rose 4.99% to $0.88. The market value of their ou
Gainers Scorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 19.22% to $0.17. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out 2 days ago. Doximity (NYSE:DOCS) stock rose 11.4% to $26.45. The market value of their outstanding shares is at $4.9 billion. As per the news, the Q4 earnings report came out today. MEI Pharma (NASDAQ:MEIP) stock increased by 10.92% to $3.25. The company's market cap stands at $21.6 million. Akso Health Group (NASDAQ:AHG) stock increased by 9.36% to $0.69. The compan
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.78) by 8.97 percent.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported